![Sung-Jae Yu](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profilo
Sung-Jae Yu currently works as a Chief Operating Officer at OSR Holdings Co., Ltd.
Posizioni attive di Sung-Jae Yu
Società | Posizione | Inizio |
---|---|---|
OSR Holdings Co., Ltd.
![]() OSR Holdings Co., Ltd. Pharmaceuticals: MajorHealth Technology OSR Holdings Co., Ltd. is a South Korean healthcare company that develops and licenses innovative biomedical therapies based on proprietary platform technologies to address unmet medical needs. The private company is based in an undisclosed location. The company wholly-owns three operating subsidiaries focused on developing therapeutic drugs in the areas of oncology and osteoarthritis, and the third is a distributor of medical devices for the treatment of neurovascular and other diseases. OSR Holdings signed a letter of intent to acquire Landmark Bioventures AG, a Swiss company that operates through four different biotech ventures with therapeutic focuses on oncology and immunology. The company was founded in 2019, and the CEO is Sean Chung. | Direttore operativo | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
OSR Holdings Co., Ltd.
![]() OSR Holdings Co., Ltd. Pharmaceuticals: MajorHealth Technology OSR Holdings Co., Ltd. is a South Korean healthcare company that develops and licenses innovative biomedical therapies based on proprietary platform technologies to address unmet medical needs. The private company is based in an undisclosed location. The company wholly-owns three operating subsidiaries focused on developing therapeutic drugs in the areas of oncology and osteoarthritis, and the third is a distributor of medical devices for the treatment of neurovascular and other diseases. OSR Holdings signed a letter of intent to acquire Landmark Bioventures AG, a Swiss company that operates through four different biotech ventures with therapeutic focuses on oncology and immunology. The company was founded in 2019, and the CEO is Sean Chung. | Health Technology |
- Borsa valori
- Insiders
- Sung-Jae Yu